Document is current

Any future updates will be listed below

HDAC inhibitor tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR-positive HER2-negative advanced breast cancer after CDK4/6 inhibitors treatment: clinical findings and exploratory circulating tumor cell and ctDNA biomarker analyses of a multicenter, phase 2 study (SYSUCC-020 trial)

Crossref DOI link: https://doi.org/10.1038/s41392-026-02632-5

Published Online: 2026-04-15

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark